Quantcast
Home manage Las Vegas Review-Journal
  Jobs Cars Homes Shopping Travel Weddings Golf Best of Las Vegas Photo   Search:

RECENT EDITIONS
Thu Fri Sat Sun Mon Tue Wed

sponsored by
News


Cancer expert goes to source

Dr. Yupo Ma gets grant for $2 million to study possible leukemia link

Dr. Yupo Ma knows it's not enough to just chop down a tree.

You've got to pull out its roots to fully finish the job, said the chief of hematopathology at the Nevada Cancer Institute.


Most Popular Stories
  • Traffic accident claims life of longtime, successful lawyer
  • NORM: Buchanan called 'larger than life'
  • Police serve search warrant at Hell's Angels clubhouse
  • Police serve search warrant at Hell's Angels clubhouse
  • Study urges Nevada and nine other states to take care in handling economy
  • THE FACES OF JOBLESSNESS: Family had to get help for first time
  • Second person dies after being restrained by police
  • Cada wins World Series of Poker championship
  • Cada wins World Series of Poker championship
  • NORM: Agassi reveals bad vibes with Shields
  • North Las Vegas motorcyclist killed in collision while racing, police say
  • Las Vegas police make arrest in 2008 slaying




  • This is sort of the approach Ma brings to his microscope every day while looking for sources behind leukemia.

    "Just like trees, cancers come from a source, and if you take out that (leukemia) source, there's a chance you can eradicate it,'' said Ma, who recently received a $2 million grant from the National Institutes of Health to further his research into whether a particular gene found in a stem cell malignancy also leads to leukemia.

    The gene he's focusing on is called SALL4. Already, in mice, Ma has found that it is present in myelodysplastic syndromes, or MDS, a group of diseases in which the bone marrow doesn't produce enough healthy blood cells. The gene is also found in acute myeloid leukemia in mice.

    In humans, Ma is trying to determine the path of the SALL4 gene -- from where it originates to where it ends up, in patients with acute myeloid leukemia. By doing this, he hopes to be able to isolate the gene and target it with a specific treatment method.

    Ma said roughly 30 to 40 percent of human myelodysplastic syndromes cases result in acute myeloid leukemia, a type of cancer that starts in the bone marrow. People with acute myeloid leukemia are more prone to infections and have an increased risk of bleeding.

    "We're trying to see the whole spectrum of the evolution of the disease, from MDS to leukemia in humans,'' Ma said.

    "There are a lot of options for treatment, but there's no cure,'' said Ma, who is also responsible for diagnosing leukemia and lymphomas at the Nevada Cancer Institute.

    MDS has become more prevalent among elderly people and there is no known cure, health officials say. Roughly 14,000 new MDS cases are diagnosed each year in the United States, Ma said.

    Ma said the country is in desperate need of a cure for leukemia.

    His lab, staffed with several other researchers, has determined that SALL4 has the ability to cause a normal cell to become cancerous.

    "Basically we're looking at something that is resistant to chemotherapy,'' he said.

    SALL4 is known to exist on cancer stem cells.

    "And we believe cancer stem cells are the root of cancers," Ma said. By targeting the stem cells and identifying their role in a cancer's progression, "then maybe a cure can be found,'' he said.

    The NIH grant, which is for five years, is one of several Ma has received to support his research into SALL4 and its relationship to the development of leukemia. Ma's lab also received a three-year, $1 million grant from the Department of Veterans Affairs.

    Contact reporter Annette Wells at awells@reviewjournal.com or (702) 383-0283.

    Newsvine Digg Fark Technorati reddit StumbleUpon del.icio.us Slashdot Propeller Mixx Furl Twitter MySpace Facebook Google Bookmarks Yahoo! Bookmarks Windows Live Favorites Ask MyStuff myAOL Favorites

    Leave Your Comment 0 Reader Comments
    Terms & Conditions
    The following comments are provided by readers and are the sole responsiblity of the authors. The reviewjournal.com does not review comments before publication nor guarantee their accuracy. By publishing a comment here you agree to abide by the comment policy. If you see a comment that violates the policy, please notify the web editor.

    Some comments may not display immediately due to an automatic filter. These comments will be reviewed within 48 hours. Please do not submit a comment more than once.
    Current Word Count:

    Note: Comments made by reporters and editors of the Las Vegas Review-Journal are presented with a yellow background.